Two Adjacent Amino Acids in the CB1 Receptor Work Together to Control How Cannabinoids Activate the Receptor
Mutating two adjacent amino acids (Ile2.62 and Asp2.63) in the CB1 receptor individually caused modest effects, but combining both mutations caused a 50-fold loss in receptor activation while binding remained intact.
Quick Facts
What This Study Found
Researchers used site-directed mutagenesis to study two adjacent amino acid positions in the CB1 receptor's second transmembrane helix.
Mutating the charged residue Asp2.63 to asparagine (removing the charge) reduced the potency of four different cannabinoid agonists for receptor activation without changing their ability to bind the receptor. The charge-conserved mutation (D2.63E) behaved like the normal receptor.
The Ile2.62 mutation alone similarly affected activation potency without altering binding affinity.
The dramatic finding was that combining both mutations (I2.62T-D2.63N double mutant) produced a synergistic approximately 50-fold increase in the concentration needed for agonist-mediated activation. This synergistic loss of function, far beyond what either mutation caused alone, showed these two residues work together as a critical switch for signal transduction.
Key Numbers
D2.63N: reduced agonist potency without affecting binding. I2.62T: similar effect. Double mutant I2.62T-D2.63N: approximately 50-fold increase in EC50 (synergistic loss). D2.63E (charge-conserved): behaved like wild type.
How They Did This
Site-directed mutagenesis of the human CB1 receptor stably expressed in HEK-293 cells. Mutant receptors were assayed for ligand binding affinity (radioligand binding) and agonist-induced activation (GTPgammaS binding) with four structurally diverse cannabinoid agonists.
Why This Research Matters
Understanding exactly how the CB1 receptor converts ligand binding into cellular activation is essential for designing drugs that can bind the receptor but modulate its activity in specific ways, potentially separating therapeutic from unwanted effects.
The Bigger Picture
This study revealed that signal transduction in the CB1 receptor depends on a precise molecular switch involving two adjacent residues. This level of molecular detail enables the rational design of drugs that interact with the receptor in specific ways.
What This Study Doesn't Tell Us
In vitro receptor studies in cell lines may not capture the full complexity of receptor behavior in neurons. Only four agonists were tested. The functional significance of the identified residues in physiological contexts was not examined.
Questions This Raises
- ?Could drugs be designed that exploit the signal transduction switch to activate CB1 partially, producing therapeutic effects without full activation?
- ?Do natural genetic variants at these positions affect cannabinoid sensitivity?
Trust & Context
- Key Stat:
- Double mutation caused synergistic 50-fold reduction in CB1 receptor activation
- Evidence Grade:
- This is a molecular pharmacology study providing detailed mechanistic insights about receptor function. It is far from clinical application.
- Study Age:
- Published in 2008. Crystal structures of the CB1 receptor (solved 2016-2017) have provided additional structural context for these mutagenesis findings.
- Original Title:
- Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 325(1), 341-8 (2008)
- Authors:
- Kapur, Ankur(2), Samaniego, Patrick, Thakur, Ganesh A(10), Makriyannis, Alexandros, Abood, Mary E
- Database ID:
- RTHC-00316
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why does this matter for medicine?
If scientists understand exactly how the CB1 receptor is activated at the molecular level, they can design drugs that partially activate it or activate it differently, potentially achieving therapeutic effects (pain relief, anti-nausea) without the full psychoactive profile.
What does "synergistic" mean here?
Each individual mutation reduced receptor activation modestly. But combining both mutations caused a 50-fold reduction, far more than you'd expect by simply adding the two individual effects together. This means the two residues work as a coordinated unit.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00316APA
Kapur, Ankur; Samaniego, Patrick; Thakur, Ganesh A; Makriyannis, Alexandros; Abood, Mary E. (2008). Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.. The Journal of pharmacology and experimental therapeutics, 325(1), 341-8. https://doi.org/10.1124/jpet.107.133256
MLA
Kapur, Ankur, et al. "Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.." The Journal of pharmacology and experimental therapeutics, 2008. https://doi.org/10.1124/jpet.107.133256
RethinkTHC
RethinkTHC Research Database. "Mapping the structural requirements in the CB1 cannabinoid r..." RTHC-00316. Retrieved from https://rethinkthc.com/research/kapur-2008-mapping-the-structural-requirements
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.